Bivalirudin May Reduce the Need for Red Blood Cell Transfusion in Pediatric Cardiac Patients on Extracorporeal Membrane Oxygenation
Retrospective study published in ASAIO J (2021)
Abstract
We retrospectively compared anticoagulation with heparin and bivalirudin for 32 consecutive children under 18 years old during extracorporeal membrane oxygenation (ECMO) in our pediatric cardiac intensive care unit (PCICU). Between September 2015 and January 2018, 14 patients received heparin, 13 venoarterial (VA), and 1 venovenous (VV). From February 2018 to September 2019, 18 received bivalirudin (all VA). The mean (standard deviation [SD]) percentage of time with therapeutic activated partial thromboplastin time and activated clotting time was bivalirudin 54 (14%) and heparin 57 (11%), p = 0.4647, and percentage of time supratherapeutic was bivalirudin 18 (10%) and heparin 27 (12%), p = 0.0238. Phlebotomy-associated blood loss per hour of ECMO was double in the heparin compared with bivalirudin group 1.08 ml/h (0.20 ml/h), compared with 0.51 ml/h (0.07 ml/h), p = 0.0003, as well as interventions to control bleeding. Packed red blood cell (PRBC) transfusions significantly correlated with higher blood loss in the heparin group (Pearson correlation coefficient = 0.49, p = 0.0047). Overall amount of blood product utilization was not different between the groups. Survival to ECMO decannulation was 89% for bivalirudin and 57% for heparin, p = 0.0396, although 6 month survival was not significantly different (67% versus 57%, p = 0.5809). Heparin may increase the need for PRBC transfusions and strategies to attenuate bleeding when compared with bivalirudin for children receiving ECMO in PCICU.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Bivalirudin had half the phlebotomy-associated blood loss versus heparin (0.51 vs 1.08 mL/h, p=0.0003) and 89% versus 57% ECMO decannulation survival (p=0.0396).
Why This Matters for Hirudotherapy
This retrospective study compared heparin (n=14) versus bivalirudin (n=18) for anticoagulation during ECMO in 32 consecutive children under 18 in a pediatric cardiac ICU, reporting that bivalirudin was associated with significantly less phlebotomy-associated blood loss (heparin 1.08 ml/h [SD 0.20] vs bivalirudin 0.51 ml/h [SD 0.07], p=0.0003), fewer bleeding-control interventions, and a lower mean percentage of time in the supratherapeutic range (bivalirudin mean 18% [SD 10%] vs heparin mean 27% [SD 12%], p=0.0238), though overall blood product utilization was not different. Bivalirudin is a direct thrombin inhibitor derived from hirudin, the anticoagulant in medicinal leech saliva, making this study relevant to ASH members interested in clinical applications of hirudin-based therapeutics from the leech secretome. Survival to decannulation favored bivalirudin (89% vs 57%, p=0.0396), but 6-month survival was not significantly different. The main limitations are the retrospective design, small sample size, and that all bivalirudin patients were VA ECMO while the heparin group included one VV patient.
Citation
Bivalirudin May Reduce the Need for Red Blood Cell Transfusion in Pediatric Cardiac Patients on Extracorporeal Membrane Oxygenation.
Machado DS et al. · ASAIO journal, 2021
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026